Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer
Year: 2025
Type: article
Abstract: Selpercatinib and pralsetinib are approved for RET-rearranged non – small cell lung cancer. Efficacy and safety were compared using matching-adjusted indirect comparison. Median progression-free survival (PFS) was 22.1 and 13.3 months for selpercatinib and pralsetinib, respectively (HR = 0.67; 95% CI, 0.53–0.85). Objective response rate was 64.5% and 65.8%, and disease control rate was 92.1% and 90.4%, respectively. Median overall survival was not reached for selpercatinib and 43.9 months for pralsetinib (HR = 0.81; 95% CI, 0.60–1.09). Grade ≥ 3 treatment-related adverse events (TRAEs) were reported in 39.3% and 62.6% of patients, with discontinuations due to TRAEs in 3.6% and 10.0% of patients, respectively. Outcomes were similar; however, PFS was significantly prolonged with selpercatinib, with fewer grade ≥ 3 TRAEs.
Source: Figshare
Authors: Hochmair, Maximilian, Kiiskinen, Urpo, D’yachkova, Yulia, Puri, Tarun, Wang, Xuwen, Wolowacz, Sorrel, Vickers, Adrian, Nadal, Ernest
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W6902284933
FWCI:
Cites:
Cited by:
Related to: